Documents

A list of downloadable documents created during development.

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): EIA form (scoping)

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): EIA form (guidance development)

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final appraisal determination

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appraisal consultation

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): assessment report

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): protocol

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final scope

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final matrix

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): comments on the draft scope

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Comments on the provisional matrix

Colorectal cancer (metastatic) following the failure of first line chemotherapies - bevacizumab, cetuximab and panitumumab (review): draft scope

Colorectal cancer (metastatic) following the failure of first line chemotherapies - bevacizumab, cetuximab and panitumumab (review): provisional matrix